Sequenom Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans for Georgia, Indiana, Kentucky, Missouri, Ohio, Virginia and Wisconsin

SAN DIEGO, May 3, 2016 /PRNewswire/ -- Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into agreements with Blue Cross and Blue Shield of Georgia, Inc. (effective 4/11/16), Anthem Blue Cross and Blue Shield Health Plans for Indiana, Kentucky, Missouri, Ohio and Wisconsin (effective 5/15), and Anthem Blue Cross and Blue Shield in Virginia (effective 5/23/16).  


The agreements provide in-network coverage for Sequenom Laboratories™' noninvasive prenatal tests for both high and average-risk pregnancies to Anthem's members in those states.  The Georgia agreement does not include HMO plans, and the Virginia agreement does not include HealthKeepers products.

"Becoming an in-network provider with leading health insurers, particularly for average risk pregnancies, is a critical component of our commercialization plan," said Dirk van den Boom, Ph.D., President and CEO of Sequenom.  "The addition of these seven states to our Anthem Blue Cross and Blue Shield relationship represents meaningful progress in our efforts to bring the benefits of noninvasive prenatal testing to women throughout the United States."

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a pioneering genetic testing company dedicated to women's health through the development of innovative products and services.  The Company serves patients and physicians by providing early patient management information.  For more information, visit

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT®, HerediT® UNIVERSAL, MaterniT® GENOME, MaterniT® 21 PLUS, NextView®, SensiGene® and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists.  Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Visit and follow @SequenomLabs.

SEQUENOM®, HerediT®, MaterniT®, NextView®, SensiGene®, VisibiliT and Sequenom Laboratories are trademarks of Sequenom, Inc.  All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the development of innovative products and services and the ability to bring the benefits of noninvasive prenatal testing to women throughout the United States.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission.  All forward-looking statements contained in this press release speak only as of the date on which they were made.  The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Logo -


SOURCE Sequenom, Inc.

For further information: Paul Goodson, Senior Director, Investor Relations and Corporate Communications, Sequenom, Inc., 858-202-9427,

print email rss pdf